Eli Lilly's Market Dominance: Surging U.S. Adoption, Blowout Tirzepatide Sales, and Foundayo Oral Launch Success
Eli Lilly & Co. (NASDAQ: LLY) has cemented its position as the undisputed global leader in the GLP-1 market, capturing 60% of the U.S. market and 53% of international sales as of Q1 2026. This dominant market position is backed by explosive consumer adoption in the United States and massive commercial momentum for its dual-acting incretin, tirzepatide.
Surging U.S. Consumer Adoption
A Gallup national health survey conducted in June 2026 revealed a dramatic expansion in public adoption of GLP-1 therapies:
- 11% of U.S. adults are currently taking a GLP-1 medication for weight management, nearly tripling from 3% in 2024.
- 15% of U.S. adults report having used these medications at some point (up from 6% in 2024).
- Public awareness of GLP-1 obesity treatments has reached 90%, compared to 80% in 2024.
Financial Blowout and Guidance Upgrades
Tirzepatide—marketed as Mounjaro for Type 2 diabetes and Zepbound for obesity—dethroned Merck's cancer blockbuster Keytruda late last year to become the world's best-selling drug.
- In Q1 2026, combined tirzepatide sales reached a staggering $12.82 billion, representing 65% of Lilly's total top line ($19.8 billion, a 56% year-over-year surge).
- Backed by this momentum, Lilly management raised its full-year 2026 revenue guidance by $2 billion to a range of $82.2 billion to $85.0 billion, and lifted its EPS outlook to $35.50–$37.00.
- The stock has surpassed a $1 trillion market capitalization, trading at roughly $1,222 per share (approximately 33x forward earnings).
Foundayo Oral Launch Success
Lilly's newly approved oral small-molecule GLP-1 receptor agonist, Foundayo® (orforglipron), has experienced unprecedented early uptake since its launch in early April 2026. As the first oral GLP-1 for obesity with no food-timing restrictions, it represents a major threat to Novo Nordisk's oral Wegovy tablet. Lilly reported that more than 20,000 patients initiated Foundayo therapy in its first week on pharmacy shelves.
Medicare GLP-1 Bridge Program Integration
To support the launch of the federal Medicare GLP-1 Bridge program on July 1, 2026, Lilly announced special access details for Medicare Part D patients. Eligible seniors can obtain Foundayo or the Zepbound KwikPen (single-patient-use) for weight management with a copay of approximately $50 per month, significantly lowering the financial barrier for millions of seniors.
Pipeline to Watch
Lilly's next-generation "triple-G" agonist, retatrutide (targeting GLP-1, GIP, and glucagon), is currently in Phase 3 development. It has demonstrated up to 28.7% average weight loss in earlier clinical rounds. Additional Phase 3 readouts are highly anticipated in late 2026.